I remember when Glaxo Wellcome hooked up with SmithKline Beecham nearly seven years ago. Then again, that's also the last thing that I remember about GlaxoSmithKline (NYSE:GSK), as I'm not usually the one writing about the major pharmaceutical companies.
So I've invited Brian Lawler and Ryan Fuhrmann -- fresh from butting heads last month on Eli Lilly (NYSE:LLY) and tackling both sides of Pfizer (NYSE:PFE) back in February -- to come share the pro and con arguments for owning a piece of GlaxoSmithKline.
Man, that name is a mouthful. Now let's see if the bullish Brian and the bearish Ryan can give you an earful of the investing implications of GlaxoSmithKline.
Where do you stand on this high-yielding Income Investor recommendation? Read on and decide for yourself.
Duel on!
- Read the bull argument
- Read the bear argument
- Read the bullish rebuttal
- Read the bearish rebuttal
- Sound off in Motley Fool CAPS
- Vote for the winner
Glaxo and Eli Lilly are Income Investor picks. Pfizer is a Motley Fool Inside Value recommendation.
Longtime Fool contributor Rick Munarriz does not own shares in any of the companies in this story. The Fool has a disclosure policy.
